ASH 2023 | The impact of novel therapies on cardiovascular treatment-related adverse events

Daniel Addison • 15 Dec 2023

ASH 2023

General

Daniel Addison, MD, The Ohio State University Wexner Medical Center, Columbus, OH, comments on the impact of new therapies on cardiovascular (CV) treatment-related adverse events (AEs). The patterns and severity of CV AEs with novel treatments often significantly differ from those observed with traditional therapies. Dr Addison highlights that many of these AEs were not considered in the earlier stages of developing novel therapies. However, as their use increases in clinical practice, physicians and the clinical multidisciplinary team can better understand and detect potential treatment-related AEs. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.